A focused review on Lyme disease diagnostic testing: An update on serology algorithms, current ordering practices, and practical considerations for laboratory implementation of a new testing algorithm

被引:3
作者
Kenyon, Stacy M. [1 ]
Chan, Siaw Li [2 ,3 ]
机构
[1] Geisinger Hlth, Dept Lab Med, 100 N Acad Ave, Danville, PA 17822 USA
[2] Nuvance Hlth, Danbury Hosp, Dept Pathol, 24 Hosp Ave, Danbury, CT 06810 USA
[3] Nuvance Hlth, Danbury Hosp, Lab Med, 24 Hosp Ave, Danbury, CT 06810 USA
关键词
Lyme; Lyme disease; Lyme serology; Modified two -tiered testing; Lyme diagnostic test; POLYMERASE-CHAIN-REACTION; BORRELIA-BURGDORFERI DNA; CEREBROSPINAL-FLUID; SYNOVIAL-FLUID; FREQUENCY; BLOOD;
D O I
10.1016/j.clinbiochem.2021.12.001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Lyme borreliosis or Lyme disease (LD) is the most prevalent tick-borne illness in the United States. Diagnosing LD can be challenging as symptoms can be nonspecific and the ability of laboratory tests to detect infection varies based on the duration of infection and the methodology used. To date, serology testing is the primary laboratory tool employed to aid in diagnosing LD. Since the mid-1990 ' s, a two-tiered algorithm has been recommended for the optimization of specificity while maintaining high sensitivity. This mini-review aims to provide an overview of LD diagnostic testing in North America, with an emphasis on serologic algorithms, in particular the modified two-tiered testing (MTTT) algorithm, along with a discussion on provider ordering patterns and practical considerations for implementation of MTTT.
引用
收藏
页码:4 / 9
页数:6
相关论文
共 46 条
[1]   Lyme disease: diagnostic issues and controversies [J].
Aguero-Rosenfeld, Maria E. ;
Wormser, Gary P. .
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2015, 15 (01) :1-4
[2]   Diagnosis of Lyme borreliosis [J].
Aguero-Rosenfeld, ME ;
Wang, GQ ;
Schwartz, I ;
Wormser, GP .
CLINICAL MICROBIOLOGY REVIEWS, 2005, 18 (03) :484-+
[3]  
[Anonymous], 2020, Can Commun Dis Rep, V46, P125, DOI 10.14745/ccdr.v46i05a05
[4]  
[Anonymous], 2019, ZEUS ELISA BORRELIA
[5]  
[Anonymous], 2018, FDA PREMARKET NOTIFI
[6]  
[Anonymous], 2021, LIAISON Lyme IgG [package insert], Patent No. 54403
[7]  
[Anonymous], 2021, FDA PREMARKET NOTIFI
[8]  
[Anonymous], 2020, ZEUS ELISA BORRELIA
[9]  
[Anonymous], 2021, LIAISON Lyme Total Antibody Plus [package insert], Patent No. 54404
[10]  
[Anonymous], 2021, LIAISON Lyme IgM [package insert], Patent No. 54402